Subscribe or Manage Preferences
VBCR - December 2015, Volume 4, No 6 - Personalized Medicine in Rheumatology
Rosemary Frei, MSc

The multibiomarker disease activity (MBDA) scale appears to be a very versatile tool, based on results presented at the 2015 annual meeting of the American College of Rheumatology.

Swedish researchers demonstrated that the MBDA score appears to be predictive of response to second-line therapy in people with early (<12 months) rheumatoid arthritis (RA) who have insufficient response to 3 months of methotrexate (MTX) treatment. Those who had relatively higher MBDA scores were significantly more likely to respond to anti–tumor necrosis factor (anti-TNF) therapy than to nonbiologic triple therapy over the next 9 months, whereas those with relatively lower scores were more likely to respond to nonbiologic triple therapy than to anti-TNF treatment.

“This suggests that the MBDA test can be used to guide therapy choice after the first few months of MTX monotherapy in patients who failed to achieve low disease activity,” remarked Karen Hambardzumyan, a PhD candidate and research assistant in the Department of Medicine at the Karolinska Institute in Stockholm. He added that the MBDA scoring system is still considered investigational in Europe and elsewhere in the world, including the United States.

To date, the MBDA score has been approved only as a measure of disease activity.

The study involved 157 patients with early RA who initially received 3 months of MTX monotherapy but did not respond. The researchers set the cut-off for response at a Disease Activity Score (DAS) 28 of at least 3.2. The 157 nonresponders were then randomized to either nonbiologic triple therapy with MTX + sulfasalazine + hydroxychloroquine or to MTX + infliximab.

The analysis showed that, at 1 year, 79% of the 19 MTX-nonresponsive patients who were subsequently randomized to triple therapy and who had relatively lower 3-month MBDA scores responded to triple therapy. In contrast, only 36% of those who had relatively higher 3-month MBDA scores responded to triple therapy. Among the subjects randomized to biologic therapy, 44% with lower 3-month MBDA scores responded, compared with 58% with higher 3-month MBDA scores (see Figure).



These results were similar when response was based on European League Against Rheumatism “good” response. Moreover, the 3-month MBDA score was more predictive of response to subsequent treatment with either triple therapy or anti-TNF therapy than were C-reactive protein, erythrocyte sedimentation rate, or DAS28.

The study was supported by a grant from the Swedish Rheumatism Association, Stockholm County, and by an unrestricted grant from Schering-Plough Sweden.

Reference

Hambardzumyan K, Bolce RJ, Saevarsdottir S, et al. The multi-biomarker disease activity score in methotrexate incomplete responders predicts clinical responses to non-biological versus biological therapy in early RA. Presented at: 2015 American College of Rheumatology Annual Meeting; November 7-11, 2015; San Francisco, CA. Abstract 618.

Related Items
Multidisciplinary Approach or Aerobic Exercise for Fibromyalgia May Not Be Cost-Effective
Rosemary Frei, MSc
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Fibromyalgia
MBDA May Predict Post-TNFi Flares in Patients with Rheumatoid Arthritis
Rosemary Frei, MSc
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Personalized Medicine in Rheumatology
New Gout Classification Criteria Released
Rosemary Frei, MSc
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Gout
MBDA May Predict RA Relapses During DMARD Tapering
Rosemary Frei, MSc
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Personalized Medicine in Rheumatology
ACR and EULAR Release Joint Guidelines on Polymyalgia Rheumatica Management
Rosemary Frei, MSc
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Polymyalgia Rheumatica
Experts Recommend Exercise for Mild to Moderate Hip Osteoarthritis
Rosemary Frei, MSc
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Osteoarthritis
Last modified: January 13, 2016
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology